BioCentury
ARTICLE | Regulation

Not a test

Why Achaogen’s LPAD miss has limited readthrough to others using the pathway

June 30, 2018 12:59 AM UTC

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant infections.

That’s because Achaogen Inc.’s Zemdri plazomicin doesn’t make a good test case for whether the limited population pathway for antibacterial and antifungal drugs (LPAD) pathway will be able to accomplish its goals...

BCIQ Company Profiles

Achaogen Inc.